Skip to main content
Evidence Snapshot

Orexin receptor

CHEMBL3307226 PROTEIN FAMILY Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:04Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3307226
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Orexin receptor as ChEMBL target CHEMBL3307226, mapped to UniProt O43614. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Orexin receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3307226
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O43614
Orexin receptor type 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Orexin receptor matters

As of 2026-09-13

Orexin receptor is reviewed as Orexin receptor type 2 (UniProt O43614); Orexin receptor shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded..

Protein context
Orexin receptor type 2

Orexin receptor type 2 Sequence length is 444 aa.

Review this target as Orexin receptor, mapped to UniProt O43614. ChEMBL maps the protein component as Orexin receptor type 2. Sequence length is 444 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt O43614 Protein
Disease context
insomnia

Orexin receptor shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALMOREXANT, DARIDOREXANT, FILOREXANT.

Start review with insomnia because it currently carries approved-linked support. Linked drugs include ALMOREXANT, DARIDOREXANT, FILOREXANT, ORN-0829 HYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Orexin receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O43614, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why insomnia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types

pChEMBL Activity Distribution

← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:04Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3307226